More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma

November 24, 2011 in Cancer

Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years later, compared with patients given standard chemotherapy treatment plus rituximab, according to an article published Online First in the Lancet.

Over the past decade, combined treatment with the monoclonal antibody rituximab and a standard chemotherapy regimen CHOP (cyclophosphamide, , vincristine, and prednisone) has substantially improved outcomes in younger than 60 years. But some patients still relapse after a complete response to treatment, and the optimum to combine with rituximab has yet to be established. Recent studies suggest that intensive chemotherapy (higher doses with shortened intervals between treatments) might benefit younger patients with aggressive lymphomas.

This study, conducted by the Groupe d'Etude des Lymphomes de I'Adulte (GELA), randomly assigned 379 patients aged 18 years with early intermediate-stage diffuse large B-cell lymphoma (one of the most common and aggressive forms of non-Hodgkin's lymphoma) to receive either four cycles of dose-intensive chemotherapy (doxorubicin, cyclophosphamide, vindesine, , and prednisone) plus rituximab (R-ACVBP)* at 2 week intervals, or eight cycles of the standard treatment (R-CHOP) at 3 week intervals.

After 3 years, event-free survival (patients not experiencing unplanned treatment for lymphoma, or recurrence, or death) was significantly better for patients in the dose-intensive group compared with those receiving standard treatment (81% vs 67%), with the more intensive chemotherapy reducing the risk of experiencing an event by 44%.

Additionally, patients assigned to the intensified regimen had a 56% lower risk of death and were 52% less likely to experience disease progression compared with those given standard treatment.

But increasing the treatment intensity also significantly increased the likelihood of serious side effects. In particular, haematological and mucosal toxic effects were significantly more common in the dose-intense group, and a much higher proportion of patients experienced febrile neutropenia (38% vs 9%).

The authors say: "Intensified immunochemotherapy with R-ACVBP represents an alternative to R-CHOP to improve survival in patients younger than 60 years with diffuse large B-cell lymphoma of low-intermediate risk."

They conclude by calling for further research to identify subsets of patients who are more likely to benefit from this intensive regimen.

In a Comment, Julie Vose from Nebraska Medical Center, Omaha, USA, cautions: "This dose-intense regimen should only be used in patients in whom the expected relapse rate is sufficient to justify the higher toxic effects and cost profile."

More information: Paper online: www.thelancet.com/… 0-4/abstract

Provided by Lancet

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

New fluorescent tools for cancer diagnosis

In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...

Cancer created 18 hours ago | popularity not rated yet | comments 0

Modulating the immune system to combat metastatic cancer

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...

Cancer created 18 hours ago | popularity 5 / 5 (1) | comments 0

Scientists put bowel cancer under the microscope

Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.

Cancer created 21 hours ago | popularity 5 / 5 (1) | comments 0

Researcher identifies breast cancer fighting hormone

Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.

Cancer created 22 hours ago | popularity 5 / 5 (2) | comments 0

Ground breaking cancer research finds immune system link

(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.

Cancer created 22 hours ago | popularity 5 / 5 (4) | comments 0


Heart failure accelerates male 'menopause'

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...

First drug to improve heart failure mortality in over a decade

Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...

Death highest in heart failure patients admitted in January, on Friday, and overnight

Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...

Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.